Patel Sanj K 4

4 · Kiniksa Pharmaceuticals International, plc · Filed Oct 22, 2025

Form 4

Period: 2025-10-20

DirectorCHAIRMAN & CEO

Transactions

Exercise/Conversion
Share Option
2025-10-21−39,331→ 97,390 total
Exercise: $3.80Exp: 2027-06-28→ Class A Ordinary Share (39,331 underlying)
Exercise/Conversion
Share Option
2025-10-22−97,390→ 0 total
Exercise: $3.80Exp: 2027-06-28→ Class A Ordinary Share (97,390 underlying)
Exercise/Conversion
Class A Ordinary Share
2025-10-20$3.80/sh+121,248$460,742→ 233,042 total
Exercise/Conversion
Share Option
2025-10-20−121,248→ 136,721 total
Exercise: $3.80Exp: 2027-06-28→ Class A Ordinary Share (121,248 underlying)
Sale
Class A Ordinary Share
2025-10-20$38.81/sh−98,934$3,839,629→ 134,108 total
Sale
Class A Ordinary Share
2025-10-20$39.32/sh−22,314$877,386→ 111,794 total
Exercise/Conversion
Class A Ordinary Share
2025-10-21$3.80/sh+39,331$149,458→ 151,125 total
Sale
Class A Ordinary Share
2025-10-21$38.77/sh−39,331$1,524,863→ 111,794 total
Exercise/Conversion
Class A Ordinary Share
2025-10-22$3.80/sh+97,390$370,082→ 209,184 total
Sale
Class A Ordinary Share
2025-10-22$38.83/sh−97,390$3,781,654→ 111,794 total

Holdings

Footnotes (6)

[F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 7, 2025.
[F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.14 and $39.135. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
[F3]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $39.14 and $39.55. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
[F4]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.49 and $39.235. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
[F5]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.495 and $39.255. The price reported in this column reflects a weighted sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
[F6]The option is fully vested and exercisable.

Documents

2 files